Zacks: Analysts Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Announce Earnings of -$0.89 Per Share

Equities research analysts expect Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) to report earnings of ($0.89) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Travere Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.78) and the lowest estimate coming in at ($1.03). Travere Therapeutics posted earnings of ($0.96) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.3%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Travere Therapeutics will report full year earnings of ($3.68) per share for the current fiscal year, with EPS estimates ranging from ($4.31) to ($2.64). For the next year, analysts forecast that the company will post earnings of ($3.19) per share, with EPS estimates ranging from ($4.48) to ($1.12). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTX – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.12). Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.40 million. During the same quarter last year, the company posted ($2.37) EPS. Travere Therapeutics’s quarterly revenue was up 12.3% compared to the same quarter last year.

Several research firms have recently issued reports on TVTX. Piper Sandler initiated coverage on shares of Travere Therapeutics in a research note on Wednesday, March 30th. They set an “overweight” rating and a $42.00 target price on the stock. Zacks Investment Research lowered Travere Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, HC Wainwright initiated coverage on shares of Travere Therapeutics in a report on Monday, February 28th. They issued a “buy” rating and a $45.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $34.11.

In other news, SVP Elizabeth E. Reed sold 1,350 shares of Travere Therapeutics stock in a transaction on Monday, January 31st. The stock was sold at an average price of $27.40, for a total transaction of $36,990.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP William E. Rote sold 1,875 shares of the business’s stock in a transaction dated Monday, January 24th. The shares were sold at an average price of $24.98, for a total transaction of $46,837.50. The disclosure for this sale can be found here. Insiders have sold 22,069 shares of company stock worth $572,764 over the last 90 days. 4.31% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new stake in shares of Travere Therapeutics during the 4th quarter valued at approximately $1,338,000. Wells Fargo & Company MN raised its stake in shares of Travere Therapeutics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 60,425 shares of the company’s stock worth $1,876,000 after buying an additional 14,319 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of Travere Therapeutics in the 4th quarter worth about $1,851,000. Deutsche Bank AG grew its stake in Travere Therapeutics by 16.7% in the 4th quarter. Deutsche Bank AG now owns 397,646 shares of the company’s stock valued at $12,343,000 after acquiring an additional 56,799 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in Travere Therapeutics by 3.1% during the 4th quarter. California State Teachers Retirement System now owns 78,416 shares of the company’s stock valued at $2,434,000 after acquiring an additional 2,386 shares in the last quarter.

Shares of TVTX traded up $0.14 during trading hours on Wednesday, hitting $30.15. The stock had a trading volume of 9,185 shares, compared to its average volume of 713,888. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -9.95 and a beta of 0.74. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.64 and a current ratio of 4.70. The firm has a 50-day moving average price of $26.84 and a 200 day moving average price of $27.57. Travere Therapeutics has a fifty-two week low of $12.75 and a fifty-two week high of $31.65.

About Travere Therapeutics (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Recommended Stories